These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 15238771

  • 1. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
    AIDS; 2004 Jul 23; 18(11):1529-37. PubMed ID: 15238771
    [Abstract] [Full Text] [Related]

  • 2. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May 23; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 3. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
    Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.
    J Acquir Immune Defic Syndr; 2004 Jan 01; 35(1):22-32. PubMed ID: 14707788
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
    Cotton M, Cassim H, Pavía-Ruz N, Garges HP, Perger T, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Sievers J, Cheng K.
    Pediatr Infect Dis J; 2014 Jan 01; 33(1):57-62. PubMed ID: 23811743
    [Abstract] [Full Text] [Related]

  • 5. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C, Dejesus E, Lamarca A, Young B, Yau L, Patel L, Vavro C, Wire MB, Wannamaker P, Shaefer M.
    HIV Clin Trials; 2010 Jan 01; 11(5):239-47. PubMed ID: 21126954
    [Abstract] [Full Text] [Related]

  • 6. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
    Carosi, Lazzarin, Stellbrink, Moyle, Rugina, Staszewski, Givens, Ross, Granier, Ait-Khaled, Leather, Nichols.
    HIV Clin Trials; 2009 Jan 01; 10(6):356-67. PubMed ID: 20133266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
    Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.
    HIV Clin Trials; 2009 Jan 01; 10(2):76-87. PubMed ID: 19487177
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 01; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 11. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
    Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW, AIDS Clinical Trials Group Protocol A5143 Team.
    HIV Clin Trials; 2008 Aug 01; 9(2):91-102. PubMed ID: 18474494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA, COL10053 Study Team.
    Antimicrob Agents Chemother; 2007 Feb 01; 51(2):560-5. PubMed ID: 17088488
    [Abstract] [Full Text] [Related]

  • 15. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C, Tribut O.
    Drugs; 2005 Feb 01; 65(5):633-59. PubMed ID: 15748098
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.
    Antimicrob Agents Chemother; 2013 Dec 01; 57(12):6158-64. PubMed ID: 24080663
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
    Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA, Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    AIDS Patient Care STDS; 2011 Jul 01; 25(7):395-402. PubMed ID: 21688986
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.